Scientific Publications
24Jul, 2016
Clinically Meaningful Cognitive and Functional Improvements with Tramiprosate In Alzheimer’s Disease (AD) Patients with APOE4/4 Genotype: Subgroup Analyses from Two Phase 3 Studies
Presented at the Alzheimer's Association International Conference (AAIC) 2016 in Toronto, Canada Abstract Background: [...]
24Jul, 2016
Phase 1 Development Of ALZ-801, a Novel Beta Amyloid Anti-aggregation Prodrug of Tramiprosate With Improved Drug Properties, Supporting Bridging to the Phase 3 Program
Presented at the Alzheimer's Association International Conference (AAIC) 2016 in Toronto, Canada Abstract Background: [...]
11Mar, 2016
Efficacy of tramiprosate in APOE4 heterozygous patients with mild to moderate AD: combined sub-group analyses from two Phase 3 trials
Presented at the 14th Annual International Athens/Springfield Symposium on Advances in Alzheimer Therapies [...]
11Mar, 2016
Tramiprosate, an oral amyloid anti-aggregation agent, shows robust cognitive efficacy in APOE4/4 homozygous AD patients: efficacy and safety analyses from two Phase 3 trials
Presented at the 14th Annual International Athens/Springfield Symposium on Advances in Alzheimer Therapies [...]
27Oct, 2015
Cognitive and Functional Efficacy of Tramiprosate in APOE4+ Patients with Mild to Moderate Alzheimer’s Disease: Subgroup Analyses of the Phase 3 North American and European Trials
Presented at the 8th Clinical Trials on Alzheimer’s Disease Congress in Barcelona, Spain [...]
20Mar, 2015
Analyses of tramiprosate Phase 3 trials show improvement in cognition and function in APOE4 positive alzheimer’s disease subjects reaching 4 point improvement from placebo on ADAS-cog in homozygous APOE4 subjects, and support development of ALZ-801, a novel prodrug of tramiprosate with optimized drug properties
Presented at the 12th International Conference on Alzheimer’s and Parkinson’s Diseases in Nice, France. [...]